Jounce Therapeutics Inc (NASDAQ:JNCE) has been assigned a consensus rating of “Buy” from the nine research firms that are covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $11.92.

A number of brokerages recently weighed in on JNCE. Zacks Investment Research cut Jounce Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 15th. HC Wainwright set a $13.00 price target on Jounce Therapeutics and gave the stock a “buy” rating in a research report on Monday, August 13th. Cowen restated a “hold” rating on shares of Jounce Therapeutics in a research report on Thursday, August 9th. JPMorgan Chase & Co. reduced their price target on Jounce Therapeutics from $12.00 to $10.00 and set a “hold” rating on the stock in a research report on Friday, August 10th. Finally, ValuEngine upgraded Jounce Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 2nd.

Shares of NASDAQ JNCE traded down $0.06 during trading hours on Thursday, reaching $4.40. 285,618 shares of the stock traded hands, compared to its average volume of 348,409. The stock has a market cap of $156.94 million, a price-to-earnings ratio of -7.72 and a beta of 4.97. Jounce Therapeutics has a 52-week low of $4.03 and a 52-week high of $29.25.

Institutional investors and hedge funds have recently bought and sold shares of the stock. NumerixS Investment Technologies Inc bought a new position in Jounce Therapeutics during the 2nd quarter worth approximately $132,000. Creative Planning bought a new stake in shares of Jounce Therapeutics in the 3rd quarter worth approximately $143,000. Trexquant Investment LP bought a new stake in shares of Jounce Therapeutics in the 3rd quarter worth approximately $216,000. Bank of America Corp DE grew its position in shares of Jounce Therapeutics by 243.4% in the 2nd quarter. Bank of America Corp DE now owns 28,607 shares of the company’s stock worth $219,000 after buying an additional 20,276 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Jounce Therapeutics in the 1st quarter worth approximately $243,000. Institutional investors and hedge funds own 84.61% of the company’s stock.

Jounce Therapeutics Company Profile

Jounce Therapeutics, Inc, a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform.

Featured Story: Stock Symbols and CUSIP Explained

Analyst Recommendations for Jounce Therapeutics (NASDAQ:JNCE)

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.